Physician profile
Ajeet Dhingra
NPI 1184625907
$8,461.92
in general payments reported to CMS, 2019-2025
38 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $664 · 2021: $1,358 · 2022: $1,316 · 2023: $2,184 · 2024: $797 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,411.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,012.99 | 2019-2025 | Cequa |
| Notal Vision, INC. | $863.78 | 2023 | |
| Alcon Vision LLC | $862.13 | 2020-2025 | Clareon, Rocklatan, Rhopressa |
| Allergan, INC. | $792.17 | 2019-2022 | |
| Glaukos Corporation | $730.90 | 2020-2025 | Ce-Marked Kxla System, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Johnson & Johnson Surgical Vision, INC. | $574.01 | 2019-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Abbvie INC. | $321.70 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Kala Pharmaceuticals, INC. | $284.91 | 2019-2022 | |
| Oyster Point Pharma, INC. | $272.21 | 2022-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $234.81 | 2024-2025 | Vevye, Triesence |
| Rxsight INC | $218.80 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Akorn Operating Company LLC | $191.66 | 2021 | |
| Genentech USA, INC. | $183.04 | 2020-2025 | Susvimo |
| Horizon Therapeutics Plc | $169.33 | 2022-2023 | Tepezza |
| Amgen INC. | $165.74 | 2024-2025 | Tepezza |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $158.81 | 2024-2025 | Humphrey Hfa, Forum |
| Bausch & Lomb Americas INC. | $158.34 | 2022-2025 | Scoutpro Osmolarity System, Xiidra, Miebo |
| Mallinckrodt Hospital Products INC. | $152.13 | 2022 | |
| Aerie Pharmaceuticals, INC. | $138.50 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $132.45 | 2019-2021 | |
| Dompe US, INC. | $128.45 | 2021-2025 | Oxervate |
| New World Medical,INC. | $113.97 | 2023 | |
| Biotissue Holdings INC. | $108.78 | 2021-2025 | |
| Thea Pharma INC. | $86.92 | 2022-2023 | Iyuzeh |
| Iridex Corporation | $55.38 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $51.24 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $49.56 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.01 | 2021 | |
| Springworks Therapeutics, INC. | $28.70 | 2025 | Gomekli |
| Glaxosmithkline, LLC. | $25.88 | 2025 | Blenrep |
| Eyepoint US, INC. | $24.42 | 2019 | |
| Coopervision INC. | $24.05 | 2023 | Myday Contact Lens |
| Astellas Pharma US INC | $23.23 | 2025 | Izervay |
| Akorn, INC. | $23.06 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $17.37 | 2019 | |
| Ocular Therapeutix, INC. | $17.22 | 2019 | |
| Omeros Corporation | $14.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajeet Dhingra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.